



### **ICTRP** Registry Profile

When complete, this form should be returned to the ICTRP Secretariat by emailing to ictrpinfo@who.int.

#### Instructions

This form is to be completed by all registries applying for the status of Primary Registry in the WHO Registry Network. Please refer to the ICTRP web site for detailed guidance on how to submit an application (http://www.who.int/ictrp/en/).

Before completing this form it is strongly recommended that the Registry Administrator obtain a copy of the International Standards for Clinical Trial Registries. These Standards can be obtained by asking the ICTRP Secretariat for access to the Registry Network Sharepoint. The Sharepoint contains a number of useful documents including the Standards, which provide detailed information on the expectations of Primary Registries. The numbering of each item in the Standards is directly compatible with the numbering of each item on this profile form.

ALL questions on this form must be answered before the form is submitted. Incomplete applications will result in a delay in the consideration of your application.

The answer to all questions on this form (except those marked with an asterisk \*) must be "yes" if a registry is to be considered potentially eligible for Primary Registry status.

Questions marked with an asterisk (\*) provide valuable background information and must be completed.

If a registry achieves Primary Registry status then the profile will be published on the ICTRP web site.

#### Updating

All Primary Registries are required to keep their profile up-to-date. Once each year, each Primary Registry will be required to resubmit an updated profile. This annual profile will be used to monitor registries and ensure continued compliance with ICTRP requirements. All profiles will be published on the ICTRP web site.

### Approval Process for new applications

The completed Registry Profile should be submitted to the ICTRP Secretariat, along with the letter/s of support from the relevant ministry and/or other relevant national or regional agency/ies demonstrating that the registry has at least a national remit. The application will be reviewed by the ICTRP Primary Registry Panel and the registry will receive formal notification of the result of their application within 12 weeks of the application deadline. Submission deadlines and more details on the approval process are available on the ICTRP web site: http://www.who.int/ictrp.





## Basic Information

I.	Name of person completing this form	Yasuo limura
II.	Role of the person completing this form (that is, the role of this person in the registry making this application)	Director of Office of Promotion of Clinical Trials, Research and Development Division, Health Policy Bureau, Ministry of Health, Labour and Welfare
III.	Date this form was completed	11 /10 / _2023 ddmmyyyy
IV.	Signature of person completing this form	Yasuo limura  Masuo Limura
V.	Official Name of Registry (list abbreviation used, if relevant) Eg Australian and New Zealand Clinical Trials Registry (ANZCTR)	Japan Registry of Clinical Trials (jRCT)
VI.	Registry postal address	100-8916
VII.	Registry street address (if different to postal address)	Kasumigaseki 1-2-2, Chiyoda, Tokyo, Japan
/111.	Registry URL (Registry's web site address)	https://jrct.niph.go.jp/
IX.	Registration URL (Web site where users go to register a trial)	https://jrct.niph.go.jp/
X.	Application type	Application for Primary Registry status Application for Partner Registry status
XI.	What is the name of the agency (or agencies) that funds the registry?	Ministry of Health, Labour and Welfare
XII.	What is the name of the agency that manages the registry?	Ministry of Health, Labour and Welfare National Institute of Public Health



XIII. Does the registry have an Advisory Board? *	Yes No □ ⊠
XIV. If the registry has an Advisory Board, please describe its terms of reference, which organizations are represented on the Board, and how often it meets. If necessary, please attach this information to the application as a separate document.	
XV. Is registration of a clinical trial a legal requirement in the country (or countries) covered by the registry? *  If yes, please provide the title of the relevant law and information on how a copy of the law can be obtained (including the relevant web address)	Yes No Clinical Trials Act http://www.mhlw.go.jp/file/06-Seisakujouhou-10800000- lseikvoku/0000163413.pdf (Only Japanese)  Act on the Safety of Regenerative Medicine https://www.mhlw.go.jp/content/10800000/000428265.pdf (Only Japanese)  PFSB/ELD Notification No. 0831-9 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW, dated August 31, 2020. https://www.mhlw.go.jp/content/11120000/000665717.pdf (Only Japanese)
XVI. Is registration of a clinical trial a requirement to obtain ethics approval in the country (or countries) covered by the registry? *  If yes, please provide the title of the relevant document describing this requirement and information on how this document can be obtained (including the relevant web address)	Yes No
XVII. Is the registry currently accepting clinical trials for registration?	Yes No □



XVIII. How many trials are on your database?				
On01_/06_/2023 there were11516 trials on the reg	istry database.			
Note: The ICTRP cannot consider a registry for Primary Registry status until it contains at least 10 trials submitted directly by Responsible Registrants. It is not acceptable for a registry to only include trial information that has been downloaded and imported from another registry.				
XIX. Does the registry agree in principle to comply with the International Standards for Clinical Trial Registries?	Yes No			





## 1. Content

# 1.1. The Registry will accept prospective registration of interventional clinical trials submitted by Responsible Registrants

1.1.1. Does the Registry register trials before the first participant has been recruited?	Yes	No
a) Does the Registry query submissions where registration is being sought after the first participant has been recruited?	Yes	No
b) Does the Registry make it clear to Responsible Registrants that prospective registration means that a trial must complete the registration process, <u>and</u> have a trial registration number issued, <u>before</u> the recruitment of the first participant.	Yes	No
1.1.2. Does the Registry register trials that have already recruited the first participant? (Also referred to as retrospective registration)	Yes	No
1.1.3. Does the Registry register other types of studies, including observational studies	Yes	No
1.1.4. Does the Registry register all trials submitted by Responsible Registrants	Yes	No
a) Does the Registry accept trials submitted by Responsible Registrants?	Yes	No
b) Does the Registry ask the person submitting a trial for registration to verify that they meet the terms and conditions for being a Responsible Registrant before being able to proceed to trial registration.	Yes	No
c) Does the Registry use the contact details provided by the Responsible Registrant to verify that those details are correct?	Yes	No
d) As a minimum, Registries must send an email to the address given and receive a reply from that same address. When possible, the telephone number and/or surface mail address will also be verified in a similar fashion.	Yes	No
e) Does the Registry ensure that all Responsible Registrants are associated with an institution or organization?	Yes	No
f) Does the Registry obtain institutional contact details for the Responsible Registrant, including name and telephone number of the institution?	Yes	No □
1.1.5. Does the Registry accept studies for registration when the data is submitted as an electronic data file (eg as an xml file)  Note: This is not a requirement and is being asked for information only.	Yes	No ⊠





# 1.2. The registry will be open to all prospective registrants (either internationally or within one or more specific countries) (ICMJE requirement)

a)	Which types of study does the Registry accept for registration? ( <i>tick all</i> ⊠ Interventional studies ⊠ Observational studies	that ap <sub>i</sub>	ply)
b)	If registration is restricted in some way (eg only accepts trials from sponsor, or in a particular health care condition (eg cancer) or intervispecify how it is restricted:		
	No restriction.		
c)	From which countries does the Registry accept trials for registration:		
	Studies conducted in Japan only are registered.		
Data S	e Registry will be able to collect and publicly display the WHO Trial et (TRDS) (ICMJE requirement).	Regist	tration
a)	Does the Registry collect and display, on a publicly accessible web site, all of the items in the WHO Trial Registration Data Set	Yes	No
b)	Does the Registry have quality control procedures in place to ensure all items in the TRDS contain meaningful data?	Yes	No
c)	Does the Registry collect the optional TRDS data items? If yes, please specify:	Yes	No
	jRCT: Information of medicine, medical devices or Regenerative medical products used in clinical trials and their suppliers.  Name of auditors, data managers, monitors, biostatisticians, a project manager.		
	e Registry will make an effort to keep registered information up-to-	date.	
(a)	Does the Registry permit Responsible Registrants to update information about their trial?	Yes	No
b)	Does the Registry have a reminder system to facilitate the submission of updated information by the Responsible Registrant.	Yes	No
to upda	please state how often the Registry reminds Responsible Registrants ate their data (eg once every 6 months; once every year):  is is not a requirement and is being asked for information only.		
c)	Does the Registry display the date the trial record was last updated?	Yes	No
d)	is is not a requirement and is being asked for information only.  Does the Registry request updates from Responsible Registrants at least annually until the Registrant has recorded meaningful information about the publication of the trial results (e.g. has listed a citation in a "Publications" field)	Yes	No
Note: Th	is is not a requirement and is being asked for information only.		



_1.5. Th	ne Registry will <u>never</u> remove a trial once it has been registered.		
a)	Does the Registry ever delete a trial record from their database, or remove it from public view, once a registration number has been issued?	Yes	No
If yes, deleted	please explain the circumstances under which a record would be d:		
b)	Does the Registry inform Responsible Registrants at the time of registration that a trial cannot be deleted once it has been registered?	Yes	No
c)	Does the Registry have clear and transparent processes for dealing with requests to remove a trial record from public view, and have these processes been documented in the SOPs?	Yes	No
2. QI	uality and Validity		
2.1. Th	e Registry will have processes in place to make sure that registered ete and accurate.	d data	is
a)		Yes	No
b)	If one or more items in the TRDS submitted for registration are incomplete or not meaningful, do Registry staff contact the Responsible Registrant and attempt to obtain complete and meaningful data?	Yes	No
c)	Does the Registry's database system apply automated checking procedures (e.g. range checks, logic rules) to data items to facilitate validity checking?	Yes	No
d)	Does the Registry have processes in place for deciding whether to register trials where the Responsible Registrant remains non-compliant with requests to provide complete and meaningful data?	Yes	No
e)	Does the Registry undertake regular internal quality control audits to assess the level of completeness and accuracy of the data collected?	Yes	No
	e Registry will have documented Standard Operating Procedures (S will be aligned with the International Standards for Clinical Trial Reg		
a)	Does the Registry have written standards for all procedures and processes employed by the registry?  o These written standards are known as Standard Operating Procedures (SOPs)	Yes	No
b)	Does the Registry use these SOPs to train all staff processing trial registrations to ensure that common standards for ensuring data completeness and meaningfulness are adhered to?	Yes	No
c)	Are the internal registry-specific SOPs aligned with the WHO International Clinical Trial Registry Platform International Standards for Clinical Trial Registration?	Yes	No



	io region y was that o proceeded in place to make date that people an	or tribuile	, 0,4106
2.3.1.	Does the Registry make sure that the person registering the trial exists and that they are the appropriate Responsible Registrant?	Yes	No
2.3.2.	Does the Registry make sure that the trial exists?	Yes	No
If yes, exists.	please briefly describe what the registry does to make sure that the trial		
	t is undertaken through the fulfilment including the approval of ethical review committee.		
ŕ	Does the Registry obtain written third-party confirmation that a trial exists?	Yes	No
If yes,	please specify the method of confirmation:		
	The approval sheet of ethical review would be submitted to jRCT by the registrant.		
b)	Does the Registry display in the trial record:  a. if the registry has obtained written third party confirmation of the trial's existence, and  b. the name of the third party from whom confirmation was received (eg the name of the ethics committee)	Yes	No
	e Registry will have a publicly accessible audit trail so that changes FRDS for an individual trial can be tracked.	made	to the
a)	Does the Registry allow Responsible Registrants to update their registered trial records?	Yes	No
b)	Does the Registry make available a publicly accessible audit trail of any changes to any TRDS items?	Yes	No
c)	Does the Registry have quality control procedures in place to ensure any updated information continues to fulfil the standards for each TRDS item?	Yes	No
d)	Does the Registry use the most up-to-date information as the default display?	Yes	No
e)	Can the TRDS, as originally registered, be accessed at all times?	Yes	No □
	e Registry agrees to comply with the International Standards for Cliries (ISCTR).	inical T	[rial
a)	Done the Desistry Administrator have a thorough working knowledge		
	Does the Registry Administrator have a thorough working knowledge of the operational aspects of their registry?	Yes	No
b)			No No





## 3. Accessibility

a) Does the Registry make the WHO TRDS items for all studies in their register (ie the registry database) accessible online at no charge to the end user?  3.2. The Registry will make it possible for the WHO TRDS for all registered trials to be searched electronically (ICMJE requirement).  a) Is it possible to search the Registry online using electronic searches of text words and phrases via a simple, single search box?  b) Does the online search allow users to search in at least the condition field and the intervention field?  c) When the results of a trial identified by a search are displayed, are all items in the WHO TRDS visible?  d) Does the online search have an advanced search option?  Yes No Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) Yes No days a week?  b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week beforehand?	3.1. The Registry will make the <u>WHO TRDS</u> for all registered trials accessil public at no charge (ICMJE requirement).	ole to t	the	
a) Is it possible to search the Registry online using electronic searches of text words and phrases via a simple, single search box?  b) Does the online search allow users to search in at least the condition field and the intervention field?  c) When the results of a trial identified by a search are displayed, are all items in the WHO TRDS visible?  d) Does the online search have an advanced search option?  Yes No Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) Yes No days a week?  b) If the Registry is planning downtime, does it publish advance notice of Yes No downtime at least one (1) week beforehand?	register (ie the registry database) accessible online at no charge to		No	
of text words and phrases via a simple, single search box?  b) Does the online search allow users to search in at least the condition field and the intervention field?  c) When the results of a trial identified by a search are displayed, are all items in the WHO TRDS visible?  d) Does the online search have an advanced search option?  Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) Yes No days a week?  b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week beforehand?	searched electronically (ICMJE requirement).	trials	to be	
field and the intervention field?  c) When the results of a trial identified by a search are displayed, are all items in the WHO TRDS visible?  d) Does the online search have an advanced search option?  Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) Yes No days a week?  b) If the Registry is planning downtime, does it publish advance notice of Yes No downtime at least one (1) week heforehand?				
items in the WHO TRDS visible?  d) Does the online search have an advanced search option?  Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7) Yes No days a week?  b) If the Registry is planning downtime, does it publish advance notice of Yes No downtime at least one (1) week hetereland?				
Note: This is not a requirement and is being asked for information only.  3.3. The Registry will allow Responsible Registrants to submit a trial for registration at any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7)  days a week?  b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week heforehand?			_	
any time of day on any day of the week (24 hours a day, seven days a week).  a) Is it possible to submit a trial to the registry 24 hours a day, seven (7)  days a week?  b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week heterehand?	· ·		_	
b) If the Registry is planning downtime, does it publish advance notice of downtime at least one (1) week beforehand?				
downtime at least one (1) week beforehand?			_	
			_	
3.4. The Registry will allow their register database to be searched at any time of day on any day of the week (24 hours a day, seven days a week).				
a) Is it possible to search the register online 24 hours a day, 7 days a Yes No week?			No	





3.5. It is desirable that Registries in the WHO Registry Network also make the <u>WHO TRDS</u> available in the language(s) of the country or countries served by the registry.

a) Does the Registry accept and/or display trial information in languages others than English?  If yes, please specify the languages used: In Japanese	Yes	No
Only answer the remaining questions in this section if the answer to the above q	uestion	is <i>yes</i> .
b) Does the Registry have quality control procedures in place to ensure that all translations are accurate?	Yes	No
c) Are all TRDS items for all records also available in English?	Yes	No
d) Are all trial records translated into English by the Responsible Registrant checked by registry staff against the non-English submission before being accepted for registration?	Yes	No
e) Are all trial records translated by Registry staff checked by at least one other staff member?	Yes	No
f) If there is a discrepancy in a translation, is the translation checked by a third person?	Yes	No
g) Does the Registry make users of the Registry aware of who performed the translation (the Responsible Registrant or Registry staff) of a registered record?	Yes	No
h) If a trial is registered in more than one language then will the Registry submit the "Scientific Title", and a language identifier, to the ICTRP Search Portal for each language used?	Yes	No





## 4. Unambiguous Identification

Note: This is not a requirement and is being asked for information only.

4.1. The Registry will have in place processes to prevent the registration of a single trial more than once on their database.				
a) Does the Registry make sure that a trial that has been submitted for registration is not already been included in their register by first searching and checking their own database?	Yes	No		
b) Does the Registry have policies and procedures in place to deal with inadvertent duplicate registration of the same trial within their own register?	Yes	No		
4.2 The Registry will facilitate the retrospective linking (or bridging) on the WHO Search Portal of a single trial registered with more than one registry by entering secondary identifiers. This includes the UTN, and the unique identifiers allocated by other registries in the WHO Registry Network.				
a) Does the Registry require responsible Registrants to make an entry in the Secondary Identifiers field?	Yes	No		
b) If there are no known secondary identifiers, does the Registry require Responsible Registrants to enter 'Nil known' in the Secondary Identifiers field?	Yes	No		
c) Does the Registry require Responsible Registrants to enter a UTN?  a. The UTN may be entered into either the Secondary Identifiers field or a field designated specifically for collection of the UTN  Note: This is not a requirement and is being asked for information only.	Yes	No ⊠		
4.3. It is desirable that Primary Registries will search the ICTRP Search Portal and attempt to determine if the trial has already been registered by another Primary Registry in the WHO Registry Network or an ICMJE approved registry.				
a) Does the Registry attempt to determine whether a submitted trial has been registered in another Primary Registry or an ICMJE approved registry before registration?	Yes	No		





# 5. Technical Capacity

5.1. The Registry will submit the <u>WHO TRDS</u> for <u>all</u> records on their regist to the WHO ICTRP Central Repository.	er, in English,			
a) Will (or does) the Registry submit the WHO TRDS items for all records on their register, in English, to the WHO ICTRP Central Repository?	Yes No			
<ul> <li>Note: If a registry accepts study types other than interventional trials (i.e. observational studies) these must be provided as well.</li> </ul>				
b) Will (or does) the Registry submit records in the format requested by the WHO ICTRP (e.g. xml file) at least once per month?	Yes No			
c) Will (or does) the Registry, after the initial data transfer of all records, only submit new or updated records each time (rather than the entire data set every time)?	Yes No □			
5.2. The Registry will have access to a database that is used to store an submitted data.	id manage the			
a) Does the Registry have access to a database that is used to store and manage the submitted data?	Yes No			
b) Does the Registry use database software and hardware that guarantees reliable access to registered data and data safety at all times?	Yes No			
5.3. The Registry will have access to adequate information technology s	support.			
a) Does the Registry have access to reliable information technology support?	Yes No			
b) Does the Registry have access to all of the following?  a. reliable application, database, backup and mail servers b. good internet connectivity speed c. sound operating systems d. appropriate software for servers, desktops and laptops e. database and web development and maintenance personnel f. other skilled information technology personnel to support these systems, as required	Yes No			
<ul> <li>c) Please briefly describe the Registry's information technology information separate document may be submitted separately if necessary)</li> </ul>	rastructure. (A			
The system of jRCT is a web application developed in PHP MySQL(RDS). jRCT runs under Amazon Linux AMI with Apache serv for jRCT will be controlled to login by ID and PW.	er. Registrants			
Data servers is Amazon RDS. Web servers is Amazon EC2. For Amazon web services (AWS), the strengthened security by introducing WAF. For backup of RDS and EC2 (AMI), 14 generations of daily snapshot are stored. Each storage place is at the RDS service or AWS S3.				
5.4. The Registry will have adequate security and other provisions corruption and loss.	against data			
a) Does the Registry have documented procedures for ensuring adequate data security and other provisions to prevent data corruption and loss?	Yes No			





b) Does the Registry issue alerts in advance of website downtime?	Yes	No
If yes, please briefly describe how these alerts are circulated and who is responsible for circulating them.		
On jRCT website.		





### 6. Administration and Governance

	the country (or region) to act as the Primary Registry for that cou ed as a group of countries and not a group of states within a country		region	
a)	Does the Registry have at least a national remit?	Yes	No	
b)	Does the Registry have a letter of support, or other appropriate documentation, from the Ministry of Health or other relevant national or regional agencies?	Yes	No	
	e letters of support must be submitted to the ICTRP Secretariat as part of the application			
c)	<ul> <li>c) From which country (or countries) does the Registry have the remit to act as the national (or regional) clinical trial registry?</li> <li>Japan</li> </ul>			
d)	d) Please specify the name of the national agencies that have given their support to the Registry:			
	Ministry of Health, Labour and Wealth			
profits		e and	not-for-	
a)		Yes	No	
b)	Does the Registry publicly disclose its ownership, governance structures and not-for-profit status in a prominent place on the registry's website?	Yes	No	
c)	What is the web address for the page where the ownership, governance and not-for-profit information is displayed?			
	http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000163417.html https://jrct.niph.go.jp/			
d)	Will the Registry inform the ICTRP immediately if their ownership, governance structures or not-for-profit status change in any way?	Yes	No	
6.3. The Registry agrees that, should it cease to function, at least the <u>WHO TRDS</u> (original and updated) for all trial records will be transferred to a Primary Registry in the WHO Registry Network.				
a)	Will the Registry transfer at least the WHO TRDS (original and updated) for all trial records to another Primary Registry in the WHO Registry Network if it ceases to function?	Yes	No	
6.4. The Registry will have a strategy in place ensure the medium to long term sustainability of the registry				
	Does the Registry have a documented business plan?	Yes	No	
b)	Does the Registry's business plan include strategies to ensure its medium to long term sustainability?	Yes	No 🗆	

6.1. The Registry will have at least a national remit, and the support of government





## 7. The Trial Registration Data Set (TRDS)

# 7.1. The Registry will collect and publicly display all items in the WHO Trial Registration Data Set (TRDS)

	Item/Label	Does the registry col this data item?	Does the registry publicly display this data item?
1	Primary Registry and Trial Identifying Number	Yes No ☑ □	Yes No ⊠ □
2	Date of Registration in Primary Registry	Yes No ⊠ □	Yes No ⊠ □
3	Secondary Identifying Numbers	Yes No ⊠ □	Yes No ⊠ □
4	Source(s) of Monetary or Material Support	Yes No ⊠ □	Yes No ⊠ □
5	Primary Sponsor	Yes No ⊠ □	Yes No ⊠ □
6	Secondary Sponsor(s)	Yes No ⊠ □	Yes No ⊠ □
7	Contact for public queries	Yes No ⊠ □	Yes No ⊠ □
8	Contact for scientific queries	Yes No ⊠ □	Yes No ⊠ □
9	Public title	Yes No ⊠ □	Yes No ⊠ □
10	Scientific title	Yes No ⊠ □	Yes No ⊠ □
11	Countries of Recruitment	Yes No ⊠ □	Yes No ⊠ □
12	Health condition(s) or problem(s) studied	Yes No ⊠ □	Yes No ⊠ □
13	Interventions	Yes No ⊠ □	Yes No ⊠ □
14	Key Inclusion and Exclusion Criteria	Yes No ⊠ □	Yes No ☑ □
15	Study type	Yes No ⊠ □	Yes No ⊠ □
16	Date of first enrolment	Yes No ⊠ □	Yes No . □
17	Sample size	Yes No ⊠ □	Yes No ⊠ □
18	Recruitment status	Yes No ⊠ □	Yes No ⊠ □
19	Primary Outcome(s)	Yes No ⊠ □	Yes No ⊠ □
20	Key Secondary Outcome(s)	Yes No ⊠ □	Yes No ⊠ □
21	Ethics Review	Yes No ⊠ □	Yes No ⊠ □





	Item/Label	Does the registry collect this data item?	Does the registry publicly display this data item?
22	Completion date	Yes No ⊠ □	Yes No ☑ □
23	Summary Results	Yes No ⊠ □	Yes No ⊠ □
24	IPD sharing statement	Yes No ⊠ □	Yes No ⊠ □

# 7.2. The Registry may choose to collect and publicly display other data items. It is recommended that registries consider the following optional, additional data items:

Item/Label	Does the registry collect this data item?	Does the registry publicly display this data item?
Lay Summary / Synopsis	Yes No	Yes No
Approvals	Yes No	Yes No
Results links	Yes No	Yes No

URL	Yes No	Yes No





## 8. Partner Registries

	imary Registries in the WHO Registry Network will have the capac ther Registries.	city to	partner
a)	Is the Registry willing and able to form partnerships with other Registries that do not themselves fulfil the criteria for a Primary Registry in the WHO Registry Network?	Yes	No
b)	Does the Registry currently have any Partner Registries?	Yes	No
If yes,	please provide the name(s) of these partners:		Ц
Univers (UMIN	sity Hospital Medical Information Network Clinical Trials Registry CTR)		
c)	If the registry has partners, are they listed on the proposed Primary Registry's web site?	Yes	No
If yes, j	please provide the address of this web page:		
UMIN (	CTR: https://www.umin.ac.jp/ctr/index-i.htm		
	completed Registry Profile form is required for all Partner Registries. This profile will be d on the ICTRP's web site.		_
	imary Registries in the WHO Registry Network will ensure that poteries meet WHO minimum standards requirements.	ntial Pa	artner
a)		Yes	No
	accept a Partner Registry and their trial registration records, they will		
	make sure that the Partner Registry meets all the WHO minimum		
	standards listed in the International Standards for Clinical Trial		
	Registries?		
b)	3 - 7	Yes	No
	the Registry's Partner Registries?		
-			
	imary Registries will have procedures in place to enable exchange or Registries.	of data	with
a)	Is the Registry able to accept data (that is, as electronic data files)	Yes	No
	from Partner Registries or other appropriate data providers?		Г
Ь	Done the Degistry garage to establish a Mayourndum Of	_	
b)	Does the Registry agree to establish a Memorandum Of	Yes	No
	Understanding (MOU) or other such agreement with each Partner Registry or other data providers, as per the requirement described in	$\boxtimes$	
	the International Standards for Clinical Trial Registries?		
c)	Does the Primary Registry agree the area of coverage/responsibility	V	NI.
0)	of their Partner Registries or other data providers (such as	Yes	No
	geographical location, health condition, intervention type, etc) and	$\boxtimes$	
	incorporate this into their SOPs and instructions to Registrants to		
	avoid any confusion or unintentional duplicate registration?		
d)	Does the Primary Registry record the identification number and date	Vac	Ma
	of registration in the Partner Registry within the trial record on the	Yes	No
	Primary Registry?		
e)	Does the Primary Registry identify records that have been sourced	Yes	No
'	from Partner Registries or other data providers so users are aware of		
	the data source?		
f)	Before announcing Partner Registries, Primary Registries must have	Yes	No
	successfully imported data into the Primary Registry?	TC3	





#### **Contact Information**

#### Administrator

The Administrator is the person employed to manage the Registry and will be the primary point of contact between the Registry and the ICTRP Secretariat.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr.
Given Name	Ritei
Family Name	Uehara
Telephone number	+81-48-458-6220/6204
Fax	+81-48-469-3875
Email	uehara.r.aa@niph.go.jp

**Secondary Contact** 

The Secondary Contact must not be the same as the Administrator. Secondary contact details are requested for circumstances when the Administrator is unavailable.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr.
Given Name	Keiko
Family Name	Yukawa
Telephone number	+81-48-458-6311
Fax	+81-48-469-3875
Email	yukawa.k.aa@niph.go.jp

Information Technology Officer

The Information Technology Officer should be the person who will be responsible for submitting the data for inclusion on the ICTRP Central Repository. They should have a good understanding of all of the IT issues relevant to the registry.

Title (Dr/Prof/Mr/Mrs/Ms/Miss)	Dr.
Given Name	Mariko
Family Name	Doi
Telephone number	+81-48-458-6172
Fax	+81-48-469-3875
Email	doi.m.aa@niph.go.jp